Literature DB >> 29482740

Cannabinoids and cancer pain: A new hope or a false dawn?

Matthew R D Brown1, W Paul Farquhar-Smith2.   

Abstract

The endocannabinoid system is involved in many areas of physiological function and homeostasis. Cannabinoid receptors are expressed in the peripheral and central nervous system and on immune cells, all areas ideally suited to modulation of pain processing. There are a wealth of preclinical data in a number of acute, chronic, neuropathic and cancer pain models that have demonstrated a potent analgesic potential for cannabinoids, especially in patients with cancer. However, although there are some positive results in pain of cancer patients, the clinical evidence for cannabinoids as analgesics has not been convincing and their use can only be weakly recommended. The efficacy of cannabinoids seems to have been 'lost in translation' which may in part be related to using extracts of herbal cannabis rather than targeted selective full agonists at the cannabinoid CB1 and CB2 receptors.
Copyright © 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analgesia; CB1 receptor; CB2 receptor; Endocannabinoids; Fatty acid amide hydrolase; Malignancy

Mesh:

Substances:

Year:  2018        PMID: 29482740     DOI: 10.1016/j.ejim.2018.01.020

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

Review 1.  Medicinal cannabinoids in palliative care.

Authors:  Meera Agar
Journal:  Br J Clin Pharmacol       Date:  2018-08-12       Impact factor: 4.335

Review 2.  Treatment of Neuropathic Pain Directly Due to Cancer: An Update.

Authors:  Morena Shkodra; Augusto Caraceni
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

3.  The Effectiveness and Safety of Medical Cannabis for Treating Cancer Related Symptoms in Oncology Patients.

Authors:  Joshua Aviram; Gil M Lewitus; Yelena Vysotski; Mahmoud Abu Amna; Anton Ouryvaev; Shiri Procaccia; Idan Cohen; Anca Leibovici; Luiza Akria; Dimitry Goncharov; Neomi Mativ; Avia Kauffman; Ayelet Shai; Gil Bar-Sela; David Meiri
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-20

4.  Antiallodynic Effects of Cannabinoid Receptor 2 (CB2R) Agonists on Retrovirus Infection-Induced Neuropathic Pain.

Authors:  Wen S Sheng; Priyanka Chauhan; Shuxian Hu; Sujata Prasad; James R Lokensgard
Journal:  Pain Res Manag       Date:  2019-07-04       Impact factor: 3.037

5.  Dichotomic effects of clinically used drugs on tumor growth, bone remodeling and pain management.

Authors:  David André Barrière; Élora Midavaine; Louis Doré-Savard; Karyn Kirby; Luc Tremblay; Jean-François Beaudoin; Nicolas Beaudet; Jean-Michel Longpré; Roger Lecomte; Martin Lepage; Philippe Sarret
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

6.  Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies.

Authors:  Ava Bachari; Terrence J Piva; Seyed Alireza Salami; Negar Jamshidi; Nitin Mantri
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.